AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

Early-stage results include survival comparisons in colorectal cancer and response data across several lung cancer programs.

Rhea-AI Summary

AbbVie (NYSE: ABBV) will present updated solid-tumor clinical data at the ESMO Congress in Madrid on October 23–27, 2026. Presentations cover seven assets, including investigational therapies and approved medicines.

In a Phase 1 colorectal cancer study, Temab-A plus bevacizumab produced a 30% overall response rate, meaning tumor shrinkage meeting study criteria. Median overall survival was 14.7 months with the combination versus 10.2 months with standard care. Phase 1 ABBV-706 data showed a 56% response rate and 12.4-month median survival in previously treated small cell lung cancer. ABBV-1480 monotherapy produced a 61.9% response rate in first-line PD-L1-positive non-small cell lung cancer. Temab-A, ABBV-706 and ABBV-1480 are also being evaluated in Phase 3 trials.

18 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

How the balance works

Positive

• Moderate pointTemab-A received two FDA Breakthrough Therapy Designations, in colorectal and non-small cell lung cancers.
• Minor pointTemab-A plus bevacizumab achieved 30% response in Phase 1 colorectal cancer, with 18.2-month median follow-up.
• Minor pointTemab-A colorectal combination median survival reached 14.7 months (n=30), versus 10.2 months with standard care (n=20).
• Minor pointTemab-A Phase 1 EGFR wild-type non-squamous lung cancer results showed 50% response and 13.8-month median survival (n=48).
• Minor pointTemab-A Phase 1 EGFR-mutant non-squamous lung cancer results showed 63% response and 16.2-month median survival (n=41).

13 minor points

• Minor pointTemab-A EGFR wild-type lung cancer subgroup with c-Met 3+, ≥25% expression had approximately 19.2-month median survival.
• Minor pointTemab-A exploratory brain-metastasis analysis showed 37% intracranial response and 19.8-month median intracranial response duration in 19 patients.
• Minor pointTemab-A colorectal combination and brain-metastasis analyses showed no new safety signals.
• Minor pointTemab-A development includes ongoing Phase 3 trials in colorectal cancer and previously treated EGFR wild-type non-squamous lung cancer.
• Minor pointABBV-706 at 1.8 mg/kg showed 56% response and 12.4-month median survival in second-line-or-later small cell lung cancer (n=41).
• Minor pointABBV-706 second-line-only subgroup showed 82% response and 14.4-month median survival (n=17).
• Minor pointABBV-706 development includes an ongoing randomized Phase 3 trial against standard care in relapsed/refractory small cell lung cancer.
• Minor pointABBV-969 Phase 1 prostate cancer findings showed 90% achieved ≥50% reduction in circulating tumor DNA by cycle 3.
• Minor pointABBV-969 findings showed 78% converted from unfavorable to favorable circulating tumor cell levels, from ≥5 to <5 cells.
• Minor pointABBV-969 two PSMA PET-negative patients both achieved PSA50 responses, meaning prostate-specific antigen reductions of at least 50%.
• Minor pointABBV-1480 first-line PD-L1-positive lung cancer monotherapy showed 61.9% response and 15.2-month median progression-free survival (n=22).
• Minor pointABBV-1480 plus docetaxel at the 20 mg/kg dose showed 66.7% response and 8.5-month median progression-free survival (n=21).
• Minor pointABBV-1480 development includes Phase 3 AMUR-Lung-01 and a newly initiated Temab-A combination study in non-small cell lung cancer.

Negative

• Minor pointABBV-1480 monotherapy's most common grade ≥3 treatment-related adverse events were hypertension and proteinuria.
• Minor pointABBV-1480 combination's most common grade ≥3 treatment-related adverse events were decreased neutrophil, white blood cell and lymphocyte counts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine
• AbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of development
• Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere^®(mirvetuximab soravtansine-gynx)

NORTH CHICAGO, Ill., Oct. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.

Collectively, the findings across Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Elahere^® (mirvetuximab soravtansine-gynx) and Emrelis™ (telisotuzumab vedotin-tllv) demonstrate how AbbVie is leveraging its deep expertise in cancer biology to advance differentiated approaches that address the complexity and heterogeneity of solid tumors and help meet the diverse needs of cancer patients worldwide.

"The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation," said Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie. "Across multiple tumor types and stages of development, we are seeing encouraging evidence of longer-term clinical benefit, promising outcomes in biomarker-defined patient populations, and the potential of novel combinations and next-generation platforms. Together, these findings reinforce our strategy of translating scientific insights into differentiated treatment approaches with the potential to meaningfully improve outcomes for patients living with cancer."

Selected findings from AbbVie's investigational solid tumor portfolio include updated clinical, survival and translational biomarker data across multiple antibody-drug conjugates (ADCs) and bispecific antibody programs, supporting continued development across a range of solid tumors:

• Temab-A
  • Updated data continue to demonstrate encouraging clinical activity for Temab-A, an investigational, next-generation, c-Met-directed ADC with a novel topoisomerase 1 inhibitor (Top1i), across multiple solid tumor types.
  • In a Phase 1 study of patients with previously treated advanced colorectal cancer (CRC), pooled data from the safety lead-in and dose-optimization cohorts showed that Temab-A (2.4 mg/kg) in combination with bevacizumab demonstrated a 30% overall response rate (ORR) and encouraging overall survival (OS) outcomes after a median follow-up of 18.2 months. Median OS reached 14.7 months with the combination (n=30), compared with 10.2 months for standard of care (n=20), regardless of c-Met protein expression level. No new safety signals were observed.¹ This combination is being further evaluated in the ongoing global Phase 3 AndroMETa-CRC-560 study (NCT07525206).
  • In an updated analysis from the ongoing Phase 1 study of Temab-A in non-squamous non-small cell lung cancer (NSCLC), the ORR was 50% with a median OS of 13.8 months in unselected patients with epidermal growth factor receptor (EGFR) wild-type disease (n=48). Among patients with EGFR-mutant disease (n=41), ORR was observed at 63% with a median OS of 16.2 months. In patients with EGFR wild-type disease, at the c-Met 3+, ≥25% expression threshold, median OS was approximately 19.2 months. As a monotherapy, Temab-A is being further evaluated, compared to the standard of care, in the global Phase 3 AndroMETa-Lung-167 study for previously treated patients with EGFR wild-type, non-squamous NSCLC (NCT07821684). 
  • In a separate post-hoc pooled exploratory analysis of 19 patients with EGFR-mutant NSCLC and baseline brain metastases, Temab-A achieved a 37% intracranial ORR, with a median duration of intracranial response of 19.8 months. No new safety signals were observed.
  • AbbVie recently announced that Temab-A received two U.S. FDA Breakthrough Therapy Designations in CRC and NSCLC based, in part, on the data highlighted above. These designations further underscore the potential of Temab-A in addressing patient needs in these disease areas.
• ABBV-706: 
  • Updated Phase 1 findings reinforce the potential of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC), while new biomarker and translational findings further support SEZ6 as a promising therapeutic target.
  • At the selected Phase 3 dose of 1.8 mg/kg (n=41), in a heavily pre-treated population, ABBV-706 achieved a 56% ORR and 12.4-month median OS in 2L+ SCLC patients; in the 2L-only subset (n=17), ORR increased to 82% and a 14.4-month median OS was observed. Safety was comparable to previously reported data.
  • ABBV-706 is being further evaluated in an ongoing, randomized, open-label, multicenter Phase 3 trial versus standard of care in patients with R/R SCLC (NCT07365241).
• ABBV-969:
  • Biomarker findings from a Phase 1 dose escalation study (NCT06318273) of ABBV-969 demonstrated robust molecular responses in heavily pretreated (median 5 prior lines of therapy) metastatic castration-resistant prostate cancer (mCRPC) patients (n=49). By cycle 3, 90% of patients achieved a ≥50% reduction in circulating tumor DNA (ctDNA) and 78% experienced circulating tumor cell conversion from unfavorable to favorable levels (≥5 to <5 cells).
  • Among 27 patients with baseline PSMA PET assessments receiving ABBV-969 at doses ≥3 mg/kg, two were PSMA PET-negative per VISION criteria; both achieved a PSA50 response, including one patient with stable disease and one with a confirmed partial response.⁴ 
  • Together, these data further support the continued clinical development of ABBV-969, AbbVie's dual-targeting ADC approach to address tumor heterogeneity by simultaneously targeting two highly prevalent targets associated with mCRPC, prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), while delivering a Top1i payload.
• ABBV-1480 
  • New data continue to support the development potential of ABBV-1480, a PD-1 × VEGF bispecific antibody, in lung cancer and other solid tumors.
  • In a Phase 1 study of patients with first-line PD-L1-positive NSCLC, ABBV-1480 monotherapy (n=22) achieved a 61.9% ORR and a median progression-free survival (PFS) of 15.2 months.⁵ In previously treated NSCLC, ABBV-1480 combined with docetaxel at the 20 mg/kg dose (n=21) delivered a 66.7% ORR and 8.5-month median PFS.⁵ The most common grade ≥3 treatment-related adverse events for monotherapy were hypertension and proteinuria; for combination therapy, they were decreased neutrophil count, decreased white blood cell count and decreased lymphocyte count.⁵
  • ABBV-1480 continues to advance in clinical development, including the global Phase 3 AMUR-Lung-01 trial (NCT07756645) and a newly initiated combination study with Temab-A in NSCLC (NCT07874282).

Details on key presentations at ESMO 2026 are available below and the full abstracts are available through the congress online program.

Approved medicines and investigational assets referenced are being evaluated in ongoing clinical trials across multiple stages of development and disease areas, both as standalone therapies and in combination regimens. For more information on AbbVie's ongoing clinical trial programs, please visit ClinicalTrials.gov.

Note: All presentation times are listed in local Madrid time.

Abstract Title	Date/Time	Session	Abstract Number
Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer	Friday, October 23, 2026 3:15—4:00 PM	Poster Metastatic prostate cancer; Poster Area – Hall 5	2224P
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study	Saturday, October 24, 2026 09:27—09:32 AM	Rapid Oral NSCLC, metastatic; Almeria Auditorium – Hall 9	2658RO
Long-term follow-up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study	Saturday, October 24, 2026 3:20—3:25 PM	Rapid Oral Gastrointestinal Tumours, lower digestive; Alicante Auditorium – Hall 6	791RO
RC118 combined with RC148 (ABBV-1480) for advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): updated results from a randomized Phase 2 trial	Sunday, October 25, 2026 12:00—12:45 PM	Poster Oesophagogastric cancer; Poster Area – Hall 5	2910P
Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): Post hoc analysis from a phase 1 first-in-human (FIH) study in patients (pts) with brain metastases (BMs)	Monday, October 26, 2026 12:00—12:45 PM	Poster NSCLC, metastatic; Poster Area – Hall 5	2635P
Real world (RW) uptake and characteristics of patients (Pts) receiving telisotuzumab vedotin-tllv (Teliso-V) in non-small cell lung cancer (NSCLC) from a US Claims Database	Monday, October 26, 2026 12:00—12:45 PM	Poster NSCLC, locally advanced; Poster Area – Hall 5	2583P
ABBV-706: A first-in-class SEZ6-targeted topoisomerase 1 inhibitor (Top1i)-antibody-drug conjugate (ADC) with robust antitumour activity in relapsed/refractory small cell lung cancer (R/R SCLC)	Monday, October 26, 2026 10:15—10:20AM	Rapid Oral Non-metastatic NSCLC and other thoracic malignancies; Burgos Auditorium – Hall 3	3837RO
Characterization of responder outcomes in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC): Phase 3 MIRASOL (GOG 3045/ENGOT-ov55)	Monday, October 26, 2026 12:00—12:45 PM	Poster Gynaecological cancers; Poster Area – Hall 5	1268P
Assessment of mirvetuximab soravtansine (MIRV) vs investigator's choice chemotherapy (ICC) as first line of therapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) in MIRASOL (GOG 3045/ENGOT-ov55)	Monday, October 26, 2026 12:00—12:45 PM	Poster Gynaecological cancers; Poster Area – Hall 5	1308P
Time to improvement in fatigue patient-reported outcomes (PRO) with mirvetuximab soravtansine (MIRV) vs investigator-choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC)	Monday, October 26, 2026 12:00—12:45 PM	Poster Gynaecological cancers; Poster Area – Hall 5	1332P
Hematologic safety of carboplatin (Carbo) plus mirvetuximab soravtansine (MIRV) in patients (pts) with folate receptor alpha (FRα)-expressing platinum-sensitive ovarian cancer (PSOC)	Monday, October 26, 2026 12:00—12:45 PM	Poster Gynaecological cancers; Poster Area – Hall 5	1330P
FLORENZA: A phase 2, open-label, randomized study to evaluate safety, efficacy, and dose optimization of mirvetuximab soravtansine (MIRV) combination therapies for epithelial ovarian cancer (EOC)	Monday, October 26, 2026 12:00—12:45 PM	Poster Gynaecological cancers: Poster Area – Hall 5	1342TiP
Updated overall survival results from the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma with longer follow up	Monday, October 26, 2026 12:00—12:45 PM	Poster SCLC; Poster Area – Hall 5	3826P
RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): Updated results from a phase 1/2 study	Monday, October 26, 2026 12:00—12:45 PM	Poster NSCLC, Metastatic; Poster Area – Hall 5	2669P

Temab-A, ABBV-706 and ABBV-969 are investigational medicines and are not approved by any health authority worldwide. Their safety and efficacy have not been established and are being evaluated in ongoing clinical studies.

AbbVie holds exclusive rights from RemeGen to develop, manufacture and commercialize ABBV-1480 outside of Greater China. ABBV-1480 is an investigational medicine and is being evaluated in ongoing clinical studies.

Alveltamig (ZG006) is an investigational medicine being developed by Suzhou Zelgen Biopharmaceuticals and has not been approved by any health authority worldwide.

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing Information for ELAHERE^® (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv)

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About AbbVie in Oncology

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. 

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements 

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Global Media: Sourojit (Jit) Bhowmick, Ph.D. Jit.Bhowmick@abbvie.com  Mabel Martinez Mabel.Martinez@abbvie.com

Investors: Liz Shea Liz.Shea@abbvie.com

¹ Cecchini M, Cruz-Correa M, Han S, et al. "Long-term follow up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study." Abstract presented at European Society for Medical Oncology Congress, 2026. Madrid, Spain.
² Raimbourg J, Camidge R, Kim T, et al. " Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): post hoc analysis from a Phase 1 first-in-human (FIH) study in patients (pts) with brain metastases." Abstract presented at Europoean Society for Medical Oncology Congress, 2026. Madrid, Spain.
³ Chiang A, Jahchan N, Faivre E, et al. "ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumour Activity in Relapsed/Refractory Small Cell Lung Cancer (R/R SCLC)." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain.
⁴ Peer A, Tolcher A, Joshua A, et al. "Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain
⁵ Yu J, Sun Y, Wen Q, et al. "RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): updated results from a Phase 1/2 study." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-data-at-the-2026-european-society-for-medical-oncology-esmo-congress-highlighting-progress-across-its-expanding-solid-tumor-portfolio-302911997.html

SOURCE AbbVie

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AbbVie's Temab-A colorectal cancer study show ahead of ESMO 2026?

Phase 1 Temab-A at 2.4 mg/kg plus bevacizumab produced a 30% overall response rate and 14.7-month median overall survival, versus 10.2 months with standard care. The combination group included 30 patients and the standard-care group included 20. Results pooled safety lead-in and dose-optimization cohorts, regardless of c-Met protein expression.

What were AbbVie's ABBV-706 small cell lung cancer results for ESMO 2026?

At the selected Phase 3 dose of 1.8 mg/kg, Phase 1 ABBV-706 data showed a 56% overall response rate and 12.4-month median overall survival in 41 second-line-or-later patients. In the second-line-only subset of 17 patients, response was 82% and median survival was 14.4 months. Safety was comparable to previously reported data.

How exploratory were AbbVie's Temab-A brain-metastasis findings?

The Temab-A brain-metastasis findings came from a post-hoc pooled exploratory analysis of 19 patients with EGFR-mutant non-small cell lung cancer and brain metastases at baseline. Intracranial response was 37%, with a median intracranial response duration of 19.8 months. No new safety signals were observed.

Which patients were included in AbbVie's ABBV-969 biomarker analysis?

The Phase 1 dose-escalation analysis included 49 patients with metastatic castration-resistant prostate cancer and a median of 5 prior treatment lines. Among 27 patients with baseline PSMA PET assessments receiving doses ≥3 mg/kg, two were PSMA PET-negative under VISION criteria; both achieved a PSA50 response, with one showing stable disease and one a confirmed partial response.